| Document |
Document Title |
|
WO/2020/223538A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
|
|
WO/2020/216766A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning...
|
|
WO/2020/219792A1 |
The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate and vancomycin-resistant S. ...
|
|
WO/2019/222431A9 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction betw...
|
|
WO/2020/210922A1 |
The present invention relates to compounds derived from adamantyl oxadiazoles and the pharmaceutically acceptable solvates, hydrates and salts of same. These compounds are suitable for use as effective and selective inhibitors of the red...
|
|
WO/2020/212513A1 |
The present invention relates to a process according to Scheme 1 for the preparation of microbiocidal 5-trifluoromethyl-1,2,4-oxadiazole derivatives of formula (I) suitable for use, e.g., as active ingredients, which have microbiocidal a...
|
|
WO/2020/208509A1 |
The present invention discloses a compound of formula (I), wherein, R1, L1,A, k, L2, W, L4, R5, R8 and R9 are as defined in the detailed description. The present invention further discloses a process for preparing the compound of formula...
|
|
WO/2020/208511A1 |
The present invention discloses a compound of formula (I), Formula (I) wherein, R1, L1,A, L2, W1, R2f, R3f, Q, and R10 are as defined in the detailed description. The present invention also relates to a process for preparing the compound...
|
|
WO/2020/198368A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2020/180876A1 |
The present application provides a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing these compounds, and methods of using these compounds for treating cancer, ...
|
|
WO/2020/168149A1 |
Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, ...
|
|
WO/2020/167994A1 |
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
|
|
WO/2020/168152A2 |
Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selec...
|
|
WO/2020/157069A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...
|
|
WO/2020/156298A1 |
Disclosed by the present invention is an application of a malononitrile compound as represented by general formula I as a bactericide. See the description for the definition of each substituent in the formula. The compound represented by...
|
|
WO/2020/156106A1 |
Heterocyclic aryl formamides or a salt thereof, a preparation method, a weeding composition, and an application. The structural formula of the heterocyclic aryl formamide compound or the salt thereof is as shown in formula I, and the com...
|
|
WO/2020/152718A1 |
The present invention provides polymorphic form M1, M2 and M3 of ozanimod. It also provides amorphous solid dispersions of ozanimod.
|
|
WO/2020/148403A1 |
The present invention is directed to 5-membered heteroaryl compounds containing a hydroxamate moiety of Formula I, pharmaceutically acceptable salts or solvates thereof, and their use as sensitizers for chemotherapy of malignant tumors.
|
|
WO/2020/138228A1 |
Provided are a jasmonic acid endogeny promoting agent and a method for promoting jasmonic acid endogeny using the same, said agent containing a compound shown in formula (1) or a salt thereof as an active ingredient. In formula (1), R1 a...
|
|
WO/2020/138935A1 |
The present invention relates to a novel compound and a medicinal use of the novel compound. In particular, the present invention relates to a novel compound useful for the treatment and/or prevention of muscular dystrophy, including Duc...
|
|
WO/2020/127960A1 |
The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
|
|
WO/2020/127685A1 |
The present invention relates to a compound according to formula I (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositio...
|
|
WO/2020/128675A1 |
Substances effective against tuberculosis based on substituted 1,2,4-oxadiazoles of general formula I, where Y = S or CH2 and R = phenyl- or phenyl- substituted in positions 2, 3, 4, and 5 by one or several electron-acceptor groups or el...
|
|
WO/2020/115200A1 |
The presented invention relates to a process for preparation of compound of formula (1) or a salt thereof (i.e.) ozanimod : (1). The invention also relates to intermediates used in the process.
|
|
WO/2020/108518A1 |
The present invention relates to the technical field of pesticides, and specifically relates to an N-(1, 3, 4-oxadiazole-2-yl)aryl formamides or a salt thereof, a preparation method therefor, a herbicidal composition and a use thereof. T...
|
|
WO/2020/100959A1 |
The purpose of the present invention is to provide a compound having PIM inhibiting activity. Examples of the compound according to the present invention include a 1,3,4-oxadiazolone compound represented by formula [1], a pharmaceutica...
|
|
WO/2020/083336A1 |
The present invention relates to the field of medicinal chemistry, and relates to a class of 1,3,4-oxadiazole-2-cyclobutyl compounds or a pharmaceutically acceptable salt, hydrate, solvate or crystal thereof, and a preparation method the...
|
|
WO/2020/085373A1 |
The present invention provides a novel compound which has activating activity selective for ERβ. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...
|
|
WO/2020/078732A1 |
Compounds of formula (I): (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2020/081143A1 |
Pyrrole and pyridine derivatives and methods of synthesizing the derivatives/analogs are provided. In particular, the compounds are useful for the treatment of antiviral infections such as HIV and influenza.
|
|
WO/2020/070611A1 |
The present invention relates to novel oxadiazoles of Formula (I) wherein, R1, L1, A1, A2, A3, A4, L2 and R2 are as defined in the detailed description. The present invention also relates to a combination or a composition comprising the ...
|
|
WO/2020/064818A1 |
Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process.
|
|
WO/2020/060963A1 |
The disclosure provides 1, 3, 4-oxadiazole derivatives useful for stemming bleeding and for treating cancer.
|
|
WO/2020/060299A1 |
Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as e...
|
|
WO/2020/053334A1 |
The present invention relates to an improved process for preparation of Ozanimod (I) or pharmaceutically acceptable salts thereof. The present invention also relates to an improved process for preparation of (S)-l-amino-2,3-dihydro- 1H-i...
|
|
WO/2020/047668A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers ...
|
|
WO/2020/043866A1 |
A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)
|
|
WO/2020/030093A1 |
A pharmaceutical composition containing an M-diamide compound and an application thereof. The pharmaceutical composition comprises an active ingredient A and an active ingredient B, the active ingredient A is an M-diamide compound having...
|
|
WO/2020/030092A1 |
A pharmaceutical composition containing an m-diamide compound and an application thereof. The pharmaceutical composition comprises an active component A and an active component B, wherein the active component A is the m-diamide compound ...
|
|
WO/2020/030096A1 |
A drug composition containing an M-diamide compound and application of the drug composition. The drug composition comprises an effective constituent A and an effective constituent B; the effective constituent A is the M-diamide compound ...
|
|
WO/2020/030094A1 |
Provided are a pharmaceutical composition comprising a meta-diamide compound and the use thereof. The pharmaceutical composition includes an active ingredient A and an active ingredient B, wherein the active ingredient A is a meta-diamid...
|
|
WO/2020/033413A2 |
RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some c...
|
|
WO/2020/032071A1 |
Development of a novel agricultural or horticultural bactericide is desired because considerable damage by diseases is still caused to agricultural and horticultural production and the like and because of, for example, damage by diseases...
|
|
WO/2020/019994A1 |
Disclosed is a compound having a neuroprotective effect, a preparation method therefor and a use thereof. In particular, disclosed is a compound as shown in general formula A or a pharmaceutically acceptable salt thereof. Also disclosed ...
|
|
WO/2020/015745A1 |
Provided are a compound III serving as an LSD1 inhibitor and a polymorph thereof, as well as an application of the compound and the polymorph thereof in the preparation of drugs for treating LSD1-associated diseases.
|
|
WO/2019/171234A9 |
The present invention relates to novel heterocyclic compound of Formula (I), (I) wherein, Het, L1, A, L2 and R12 are as defined in the detailed description, for use as fungicides.
|
|
WO/2020/001067A1 |
Provided are m-diamide compounds and a preparation method therefor and the use thereof. The m-diamide compounds have a structure represented by formula I. The m-diamide compounds of the present invention can have a high insecticidal acti...
|
|
WO/2020/005888A1 |
Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, Y1, Y2, L1, and G1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (...
|
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2020/005313A1 |
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
|
